Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 9/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17665552 | 0.89 | MEN1 (0.39) | AKR1C3AKR1C2MMP8AKR1B10AKR1C4 | |
| SCHEMBL3653822 | 0.83 | AKR1C3 (0.44) | ARAKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL7714873 | 0.82 | AKR1C3 (0.41) | ARAKR1C3AKR1C2AKR1B10AKR1C4 | |
| SCHEMBL2297081 | 0.81 | MMP8 (0.41) | AKR1C3AKR1C2MMP8KCNH2ALDH1A1 | |
| SCHEMBL17653973 | 0.81 | MEN1 (0.40) | AKR1C3AKR1C2MMP8AKR1B10AKR1C4 | |
| SCHEMBL11920717 | 0.80 | MMP8 (0.43) | ARMMP8MEN1KMT2AKCNH2 | |
| SCHEMBL17653962 | 0.80 | AR (0.47) | AR | |
| SCHEMBL2746779 | 0.79 | AR (0.49) | ARAKR1C3AKR1C2KCNH2ALDH1A1 | |
| SCHEMBL17665462 | 0.78 | MEN1 (0.40) | AKR1C3AKR1C2MMP8AKR1B10AKR1C4 | |
| SCHEMBL17653867 | 0.77 | CA12 (0.44) | MMP8MEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| CN-1993327-B | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO | 2013-02-06 | — | — | CN | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| CN-1993327-A | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO (JP) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | AR 1078/4885AKR1C3 1277/4885AKR1C2 1979/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | AR 1184/4885AKR1C3 650/4885AKR1C2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.